Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Supply chain

Health secretary asked for list of medicines at risk under 'no-deal' Brexit

Health and social care secretary Matt Hancock

Source: Shutterstock.com

Health and social care secretary Matt Hancock (pictured) has received a letter from Sarah Wollaston, chair of the House of Commons health and social care committee, in which she asks what measures are being put in place in case of supply issues after a ‘no-deal’ Brexit

Sarah Wollaston, chair of the House of Commons health and social care committee, has written to health and social care secretary Matt Hancock to ask him to publish a list of medicines and medical products that have been identified as at risk of supply issues in the case of a ‘no-deal’ Brexit.

In a letter to Hancock, dated 21 November 2018, Wollaston asks that the published list sets out clearly any medicines that cannot be switched without creating additional risk to patients and where careful review would be required, and the contingency plans that the Department of Health and Social Care is putting in place.

The letter expresses the committee’s concerns over a no-deal scenario in terms of patient access to medicines and medical products, the costs of contingency planning, and non-disclosure agreements.

Wollaston also asks for clarification on the rationale behind requesting companies to sign non-disclosure agreements, and for more information about the content of the agreements. She says that while non-disclosure agreements may be appropriate to protect the commercial interests of the companies involved, the committee was concerned that they might pose a barrier to the disclosure of information that may be in the public interest.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205806

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.